Received Aug 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | U6952AA | — |
maladministration/2nd dose received; This non-serious case was reported by a other health professional via sales rep and described the occurrence of extra dose administered in a 12-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number U6952AA) for prophylaxis. Previously administered products included Menveo (first dose given on 7 Feb 2020 in (lot number AMVA199A, expiry date 03 Sep 2020). On 13-AUG-2021, the patient received the 2nd dose of Menveo. On 13-AUG-2021, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: maladministration/2nd dose received). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 23-JUL-2025 The patient received a dose of Menveo at healthcare professional office at age 11. Dose given on 07 Feb 2020. According to state immunization registry, a dose of Menveo was given when patient was 12 and half years. The dose was not given in the healthcare professional office and was only noted on the registry as having been administered 13 Aug 2021 which led to extra dose administered. According to the healthcare professional, patient did not report any event at the time of the 2nd dose administration. They inquire if the patient should still get Menveo booster dose at 16 if he received 2 doses already.